Wedbush Research Analysts Cut Earnings Estimates for AVTX

Avalo Therapeutics, Inc. (NASDAQ:AVTX) – Investment analysts at Wedbush reduced their FY2025 earnings per share estimates for Avalo Therapeutics in a report released on Thursday, November 6th. Wedbush analyst R. Driscoll now expects that the company will earn ($6.73) per share for the year, down from their previous estimate of ($1.86). The consensus estimate for Avalo Therapeutics’ current full-year earnings is ($19.07) per share. Wedbush also issued estimates for Avalo Therapeutics’ Q4 2025 earnings at ($1.38) EPS, Q1 2026 earnings at ($1.44) EPS, Q2 2026 earnings at ($0.93) EPS, Q3 2026 earnings at ($0.89) EPS, Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($4.20) EPS, FY2027 earnings at ($2.31) EPS, FY2028 earnings at ($2.82) EPS and FY2029 earnings at ($2.95) EPS.

AVTX has been the subject of several other reports. Cowen initiated coverage on Avalo Therapeutics in a research note on Friday, September 5th. They issued a “buy” rating for the company. BTIG Research reissued a “buy” rating and issued a $40.00 price objective on shares of Avalo Therapeutics in a research note on Monday, September 29th. HC Wainwright boosted their price objective on Avalo Therapeutics from $15.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, September 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Tuesday, October 14th. Finally, Cantor Fitzgerald started coverage on shares of Avalo Therapeutics in a research report on Friday, August 15th. They issued an “overweight” rating for the company. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Avalo Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $31.67.

Avalo Therapeutics Stock Performance

Shares of AVTX opened at $15.50 on Monday. The firm has a market cap of $203.83 million, a PE ratio of -0.85 and a beta of 0.94. Avalo Therapeutics has a 52-week low of $3.39 and a 52-week high of $19.41. The business’s 50 day moving average price is $13.86 and its two-hundred day moving average price is $8.69.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($2.19) EPS for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.52).

Institutional Trading of Avalo Therapeutics

A number of hedge funds have recently bought and sold shares of AVTX. Nantahala Capital Management LLC grew its stake in Avalo Therapeutics by 10.6% in the 2nd quarter. Nantahala Capital Management LLC now owns 995,000 shares of the company’s stock valued at $4,965,000 after purchasing an additional 95,000 shares during the period. Vanguard Group Inc. raised its stake in shares of Avalo Therapeutics by 314.9% during the 3rd quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock worth $8,803,000 after purchasing an additional 525,696 shares during the period. Affinity Asset Advisors LLC boosted its holdings in shares of Avalo Therapeutics by 19.3% in the 1st quarter. Affinity Asset Advisors LLC now owns 657,154 shares of the company’s stock worth $5,264,000 after buying an additional 106,389 shares during the last quarter. Bank of America Corp DE grew its position in Avalo Therapeutics by 7,066.8% during the second quarter. Bank of America Corp DE now owns 406,571 shares of the company’s stock valued at $2,029,000 after buying an additional 400,898 shares during the period. Finally, RWA Wealth Partners LLC bought a new position in Avalo Therapeutics during the first quarter valued at about $2,505,000. 87.06% of the stock is currently owned by institutional investors.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.